<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia/small lymphocytic lymphoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia/small lymphocytic lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia/small lymphocytic lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kanti R Rai, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephan Stilgenbauer, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Woyach, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 26, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H5623314"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder (lymphoid neoplasm). It is characterized by a progressive accumulation of functionally incompetent B lymphocytes, which are usually monoclonal in origin.</p><p>CLL is considered to be identical (ie, one disease with different manifestations) to the mature (peripheral) B cell neoplasm small lymphocytic lymphoma (SLL), a non-Hodgkin lymphoma. The term CLL is used when the disease manifests primarily in the blood, whereas the term SLL is used when involvement is primarily nodal. (See  <a class="medical medical_review" href="/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p>Patients with asymptomatic, stable, early-stage CLL are followed closely without treatment. The selection of initial therapy for advanced stage or symptomatic CLL/SLL will be reviewed here. General issues regarding management, including the treatment of relapsed/refractory disease, and the management of complications of CLL/SLL and its treatment are discussed separately. The pathophysiology, clinical manifestations, diagnosis, staging, and prognosis of CLL are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4545.html" rel="external">"Overview of the treatment of chronic lymphocytic leukemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4504.html" rel="external">"Overview of the complications of chronic lymphocytic leukemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4520.html" rel="external">"Treatment of relapsed or refractory chronic lymphocytic leukemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4489.html" rel="external">"Staging and prognosis of chronic lymphocytic leukemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4539.html" rel="external">"Pathobiology of chronic lymphocytic leukemia"</a>.)</p><p></p><p class="headingAnchor" id="H1431005865"><span class="h1">PRETREATMENT EVALUATION</span><span class="headingEndMark"> — </span>The pretreatment evaluation documents the extent and characteristics of disease and identifies comorbidities that may impact treatment options. Our approach is consistent with that recommended by the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) [<a href="#rid1">1</a>]. Details on the Rai and Binet staging systems used in CLL are presented separately  (<a class="graphic graphic_table graphicRef56284 graphicRef80421" href="/d/graphic/56284.html" rel="external">table 1A-B</a>). (See  <a class="medical medical_review" href="/d/html/4489.html" rel="external">"Staging and prognosis of chronic lymphocytic leukemia"</a>.)</p><p>The history and physical examination should document the following findings of particular interest:</p><p class="bulletIndent1"><span class="glyph">●</span>Performance status  (<a class="graphic graphic_table graphicRef58785 graphicRef72901" href="/d/graphic/58785.html" rel="external">table 2A-B</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fatigue, night sweats, weight loss, and/or fever</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subjective changes in the size of lymph nodes, liver, and/or spleen; and/or pain in these areas</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bidirectional diameters of the largest palpable lymph nodes in the cervical, axillary, and inguinal regions, assessed by physical examination</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Measurements of the spleen and liver as palpated with respect to the costal margins</p><p></p><p>Laboratory and imaging evaluation includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with differential and reticulocyte count, chemistries with liver and kidney function and electrolytes, alkaline phosphatase, lactate dehydrogenase (LDH), beta-2 microglobulin, direct antiglobulin test (DAT), haptoglobin, and serum immunoglobulin levels. Those with autoimmune hemolytic anemia identified by a positive DAT may benefit from anti-CD20 monoclonal antibodies. (See  <a class="medical medical_review" href="/d/html/7078.html" rel="external">"Warm autoimmune hemolytic anemia (AIHA) in adults", section on 'Rituximab (alone or added to glucocorticoids)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients should undergo testing for human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C. Antiviral therapy can be initiated in patients with chronic active HBV prior to the administration of immunosuppressive therapy to decrease the risk for hepatitis B reactivation. (See  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Not all patients need a bone marrow evaluation. Unilateral bone marrow aspirate and biopsy is recommended for patients who have cytopenias of unknown cause. This sample should be sent for pathologic review, including morphology (hematoxylin and eosin stain) and immunophenotype.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of tumor cells (usually from peripheral blood) with fluorescence in situ hybridization (FISH) for del17p, del11q, trisomy 12, and del13q. FISH for t(11;14) is performed to rule out mantle cell lymphoma. <em>TP53</em> mutation and immunoglobulin heavy chain variable (IGHV) mutation status is tested by Sanger or next-generation sequencing. Testing for del17p, <em>TP53</em> mutation, and IGHV mutation status is critical for the selection of an appropriate treatment. Testing for CD38 expression and/or ZAP-70 expression are not recommended in clinical practice since IGHV testing is widely available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A lymph node biopsy is indicated in patients with suspected histologic transformation to a more aggressive histology (ie, Richter transformation [RT]). RT may be suspected if there is a sudden clinical deterioration characterized by a marked increase in lymphadenopathy at one or more sites, splenomegaly, worsening systemic symptoms (eg, fever, night sweats, weight loss), and/or elevated serum LDH. Imaging with a combined PET/CT scan can be used to determine the preferred biopsy site. (See  <a class="medical medical_review" href="/d/html/4728.html" rel="external">"Richter transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma", section on 'Image-directed biopsy'</a>.)  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A chest radiograph should be obtained to evaluate for hilar and mediastinal adenopathy. Computed tomography (CT) of the chest, abdomen, and pelvis is not required for the pretreatment evaluation and is usually reserved for patients enrolled in clinical trials [<a href="#rid1">1,2</a>]. However, a CT should be performed in any patient in whom enlarged abdominal or pelvic nodes are suspected based upon evidence of complications, such as obstructive jaundice or obstruction of the inferior vena cava or ureters.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Those with child-bearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. Contraception is needed while on therapy. (See  <a class="medical medical_review" href="/d/html/7440.html" rel="external">"Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery"</a>.)</p><p></p><p class="headingAnchor" id="H4065426385"><span class="h1">GOALS OF THERAPY</span><span class="headingEndMark"> — </span>Patients with advanced CLL/SLL are not cured with conventional therapy.</p><p>The goals of therapy are to:</p><p class="bulletIndent1"><span class="glyph">●</span>Improve quality of life</p><p class="bulletIndent1"><span class="glyph">●</span>Prolong overall survival (OS)</p><p></p><p>Treatment alleviates symptoms and reverses cytopenias. </p><p>Some modern treatments have demonstrated improved OS. However, this is a rapidly evolving field, and survival estimates for modern therapies are limited by the short follow-up of trials evaluating these approaches. In such settings, we consider improvement in progression-free survival at a follow-up of at least five years to be a reasonable finding of clinical benefit. Clinical trials are evaluating the role of measurable residual disease (MRD; also called "minimal residual disease") as a surrogate endpoint. MRD testing is reserved for patients enrolled in clinical trials and has no role in the routine care of patients with CLL/SLL.</p><p class="headingAnchor" id="H543641936"><span class="h1">CHOICE OF THERAPY</span><span class="headingEndMark"> — </span>There is no agreed upon standard front-line treatment regimen, and practice varies.</p><p>Our preferred initial therapy is dependent on  (<a class="graphic graphic_algorithm graphicRef122052" href="/d/graphic/122052.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic risk stratification of the tumor</p><p class="bulletIndent1"><span class="glyph">●</span>Patient comorbidities and medications</p><p class="bulletIndent1"><span class="glyph">●</span>Patient preference and treatment goals</p><p class="bulletIndent1"><span class="glyph">●</span>Logistics</p><p></p><p>While we offer guidance, the selection of therapy is individualized based on these factors. The optimal initial treatment of CLL/SLL is the subject of multiple ongoing studies. We always encourage patients to enroll in a well-conducted clinical trial. (See  <a class="medical medical_review" href="/d/html/4520.html" rel="external">"Treatment of relapsed or refractory chronic lymphocytic leukemia", section on 'Investigational therapies'</a>.)</p><p class="headingAnchor" id="H924766703"><span class="h2">Assess comorbidities and patient preferences</span><span class="headingEndMark"> — </span>The treatments used for CLL/SLL differ significantly in associated toxicities and burden of administration. As such, comorbidities, concomitant medications, logistics, and patient preferences weigh substantially in the final treatment decision  (<a class="graphic graphic_table graphicRef142941" href="/d/graphic/142941.html" rel="external">table 3</a>).</p><p>The main treatment options for most patients are:</p><p class="bulletIndent1"><span class="glyph">●</span>Continuous therapy with a Bruton tyrosine kinase (BTK) inhibitor, either <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> or <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> are preferred over <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fixed-duration <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a>, administered over one year.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fixed-duration <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a>, administered over 15 months.</p><p></p><p>Important patient-dependent factors that impact the choice between these options include:</p><p class="bulletIndent1"><span class="glyph">●</span>Comorbidities may overlap with expected toxicities or impact drug metabolism.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> may be preferred over BTK inhibitors in those with cardiovascular disorders, uncontrolled hypertension, and/or a high risk for bleeding (eg, low platelet counts, conditions that require anticoagulation).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A BTK inhibitor may be preferred over <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> in patients with kidney impairment; kidney impairment increases the risk of tumor lysis syndrome (TLS) with venetoclax.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> is less preferred in patients with conditions that make them poor candidates for a BTK inhibitor (eg, cardiovascular disorders, uncontrolled hypertension, and/or high risk for bleeding).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug interactions are common with targeted therapies.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>BTK inhibitors should be used with caution in patients on anticoagulation, especially <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> is avoided in patients on nephrotoxic drugs and those taking a strong CYP3A inhibitor, as both can increase the risk for TLS.</p><p></p><p class="bulletIndent1">Consultation with a clinical pharmacist may help with identifying and managing interactions. For more detailed information on potential drug-drug interactions, refer to the <a class="external" href="/drug-interactions/">drug interactions program</a> within UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment burdens differ significantly:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>BTK inhibitors are oral medications given until disease progression or unacceptable toxicity. While toxicity is greatest in the first six months of treatment, it continues for the duration of therapy. Important toxicities include bleeding, atrial fibrillation, and hypertension. Other toxicities include fatigue, rash, infections, and myalgia/arthralgia. Toxicities also play an important role in the selection among BTK inhibitors. (See <a class="local">'Choice of Bruton tyrosine kinase inhibitor'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> is a more intensive therapy given over one year, followed by a treatment-free period. Those with progression after a prolonged response can be retreated with a second one-year course. As such, in the absence of overall survival (OS) comparisons, it is clinically appropriate to compare second progression-free survival (PFS) in those treated with venetoclax plus obinutuzumab versus first PFS in those treated with a BTK inhibitor, as both of these scenarios are a more accurate reflection of treatment failure.</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> is an oral medication, and <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> is intravenous. Treatment initiation requires frequent visits to monitor for TLS. The most common toxicities are neutropenia, thrombocytopenia, anemia, diarrhea, nausea, upper respiratory tract infection, cough, musculoskeletal pain, fatigue, and edema. When administered according to the schedules used in the trials and with risk-based TLS prophylaxis, clinically significant TLS is rare.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> is a more intensive therapy given over 15 months, followed by a treatment-free period. Patients with progression after a prolonged response can be retreated with a second course. The few patients with unacceptable toxicity may be candidates for continuous therapy with a BTK inhibitor or with time-limited venetoclax plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>.</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> is an all-oral regimen. Treatment initiation incorporates prophylaxis and monitoring for TLS but is logistically easier than with venetoclax plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a>. The most common toxicities are neutropenia, diarrhea, and hypertension. Clinically significant TLS is rare.</p><p></p><p class="headingAnchor" id="H3316356575"><span class="h2">Genetic risk stratification</span><span class="headingEndMark"> — </span>Tumor genetic risk stratification impacts prognosis and informs our preferred therapies, as described below.</p><p class="headingAnchor" id="H2634199959"><span class="h3">Del(17p) and/or <i>TP53</i> mutations (very high risk)</span><span class="headingEndMark"> — </span>Patients with CLL/SLL with 17p deletion and/or <em>TP53</em> mutation are at a higher risk of not responding to therapy or experiencing early relapse. While targeted agents have improved outcomes over those achieved with chemoimmunotherapy, del(17p) and <em>TP53</em> mutation retain their prognostic impact with some targeted therapies, most clearly with venetoclax-based therapies; patients with del(17p) and/or <em>TP53</em> mutation treated with <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> have inferior outcomes when compared with other patients without <em>TP53</em> alterations [<a href="#rid3">3</a>]. As such, we encourage enrollment in a clinical trial. Outside of a clinical trial, we offer the following approach and adjust based on comorbidities, concomitant medications, patient preference, and logistics.</p><p>Preferred options:</p><p class="bulletIndent1"><span class="glyph">●</span>Continuous <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a></p><p class="bulletIndent1"><span class="glyph">●</span>Continuous <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a></p><p></p><p>Alternatives:</p><p class="bulletIndent1"><span class="glyph">●</span>Continuous <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a></p><p class="bulletIndent1"><span class="glyph">●</span>Fixed-duration <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a></p><p class="bulletIndent1"><span class="glyph">●</span>Fixed-duration <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a></p><p></p><p>For most patients with del(17p) or <em>TP53</em> mutation, we suggest continuous therapy with <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> or <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a>  (<a class="graphic graphic_algorithm graphicRef122052" href="/d/graphic/122052.html" rel="external">algorithm 1</a>). As described in more detail below, continuous therapy with a BTK inhibitor is highly effective and improves OS over that seen with chemoimmunotherapy in this population. Acalabrutinib and zanubrutinib are preferred over <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> because extrapolation of data from the relapsed setting suggests that they are at least as effective and better tolerated. These two agents have not been compared directly. However, in our practice, if the goal is best efficacy with acceptable toxicity, we offer zanubrutinib. In contrast, if the goal is best tolerability with good efficacy, we offer acalabrutinib. (See <a class="local">'Choice of Bruton tyrosine kinase inhibitor'</a> below and <a class="local">'Acalabrutinib'</a> below and <a class="local">'Zanubrutinib'</a> below and <a class="local">'Ibrutinib'</a> below.)</p><p>Fixed-duration <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> is an acceptable alternative, largely based on the extrapolation of data in older adults, patients without del(17p) and <em>TP53</em> mutation, and those with relapsed disease. It may be preferred in patients who are poor candidates for a BTK inhibitor due to comorbidities (eg, history of atrial fibrillation, moderate hepatic impairment, history of severe bleeding) or concomitant medications (eg, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>). Trials of this combination had a limited number of patients with del(17p) or <em>TP53</em> mutation. However, cross-trial comparisons suggest that efficacy of venetoclax plus obinutuzumab may be decreased in this population. (See <a class="local">'Venetoclax plus obinutuzumab'</a> below.)</p><p>Fixed-duration <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> is approved for CLL/SLL in Europe. We have the least experience with this combination, especially among patients with del(17p) or <em>TP53</em> mutation. (See <a class="local">'Ibrutinib plus venetoclax'</a> below.)</p><p>Although approved in Europe for this population, we avoid idelalisib-based regimens in previously untreated CLL due to reports of excessive toxicity. (See  <a class="medical medical_review" href="/d/html/4520.html" rel="external">"Treatment of relapsed or refractory chronic lymphocytic leukemia", section on 'PI3K inhibitors'</a>.)</p><p class="headingAnchor" id="H402183911"><span class="h3">No del(17p) and no <i>TP53</i> mutation</span></p><p class="headingAnchor" id="H3183531442"><span class="h4">Immunoglobulin heavy chain variable unmutated (high risk)</span><span class="headingEndMark"> — </span>Patients with immunoglobulin heavy chain variable (IGHV)-unmutated CLL and without del(17p) or <em>TP53</em> mutation may reasonably choose continuous therapy with <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> (possibly with <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a>) or <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a>, or fixed-duration <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus obinutuzumab depending upon comorbidities, concomitant medications, patient preference, and logistics  (<a class="graphic graphic_algorithm graphicRef122052" href="/d/graphic/122052.html" rel="external">algorithm 1</a>). (See <a class="local">'Assess comorbidities and patient preferences'</a> above.)</p><p>Preferred options:</p><p class="bulletIndent1"><span class="glyph">●</span>Continuous <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> as a single agent or with <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a></p><p class="bulletIndent1"><span class="glyph">●</span>Continuous <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a></p><p class="bulletIndent1"><span class="glyph">●</span>Fixed-duration <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a></p><p class="bulletIndent1"><span class="glyph">●</span>Fixed-duration <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a></p><p></p><p>Alternatives:</p><p class="bulletIndent1"><span class="glyph">●</span>Continuous <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> as a single agent or with <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> </p><p></p><p>These options have not been directly compared in randomized trials, but all have shown improved PFS when compared with chemoimmunotherapy in this population.</p><p>Continuous therapy with a BTK inhibitor improves both PFS and OS over that seen with chemoimmunotherapy in this population. <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">Acalabrutinib</a> and <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> are preferred over <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> because extrapolation of data from the relapsed setting suggests that they are at least as effective and better tolerated. These two agents have not been compared directly. However, in our practice, if the goal is best efficacy with acceptable toxicity, we offer zanubrutinib. In contrast, if the goal is best tolerability with good efficacy, we offer acalabrutinib. The addition of <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> to acalabrutinib appears to increase efficacy and increases toxicity with higher rates of cytopenias and infections. As such, we reserve acalabrutinib plus obinutuzumab for young/fit patients without a history of infection. Ibrutinib plus obinutuzumab has not been compared directly versus ibrutinib alone. (See <a class="local">'Choice of Bruton tyrosine kinase inhibitor'</a> below and <a class="local">'Acalabrutinib'</a> below and <a class="local">'Zanubrutinib'</a> below.)</p><p>OS data with <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> are immature. When compared with BTK inhibitors, venetoclax plus obinutuzumab is a more intensive therapy administered for one year followed by a treatment-free period. Those with progression after a prolonged response can be retreated with a second one-year course. This option may be preferred in patients who are willing to undergo a more intensive therapy in order to attain a treatment-free period and in those who are poor candidates for a BTK inhibitor due to comorbidities (eg, history of atrial fibrillation, moderate hepatic impairment, history of severe bleeding) or concomitant medications (eg, anticoagulants). (See <a class="local">'Venetoclax plus obinutuzumab'</a> below.)</p><p>While fixed-duration <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> has demonstrated deep responses, it has not been directly compared with venetoclax plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a>, and follow-up of clinical trials is short. (See <a class="local">'Ibrutinib plus venetoclax'</a> below.)</p><p class="headingAnchor" id="H224183752"><span class="h4">Immunoglobulin heavy chain variable mutated (standard risk)</span><span class="headingEndMark"> — </span>For most patients with IGHV-mutated CLL and without del(17p) or <em>TP53</em> mutation, we suggest fixed-duration therapy with <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> or <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus venetoclax rather than continuous therapy with a BTK inhibitor  (<a class="graphic graphic_algorithm graphicRef122052" href="/d/graphic/122052.html" rel="external">algorithm 1</a>). This approach is likely to offer a prolonged treatment-free period in this population. Continuous therapy with <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> or <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> are reasonable alternatives, especially for those who are poor candidates for venetoclax plus obinutuzumab or ibrutinib plus venetoclax due to kidney impairment, use of nephrotoxic drugs, and/or a strong CYP3A inhibitor. (See <a class="local">'Assess comorbidities and patient preferences'</a> above.)</p><p>Preferred options:</p><p class="bulletIndent1"><span class="glyph">●</span>Fixed-duration <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a></p><p class="bulletIndent1"><span class="glyph">●</span>Fixed-duration <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a></p><p></p><p>Alternatives:</p><p class="bulletIndent1"><span class="glyph">●</span>Continuous <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> as a single agent or in combination with <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a></p><p class="bulletIndent1"><span class="glyph">●</span>Continuous <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a></p><p class="bulletIndent1"><span class="glyph">●</span>Continuous <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> as a single agent or in combination with <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a></p><p></p><p>These options have not been directly compared in randomized trials. Patients with IGHV-mutated CLL/SLL were included in the trials that compared these treatments versus chemoimmunotherapy. In subgroup analyses, patients with IGHV-mutated CLL/SLL have superior outcomes when compared with other patients. The benefits of targeted therapies over chemoimmunotherapy seen in the general population are of lesser magnitude and do not always reach statistical significance in patients with IGHV-mutated CLL, although the studies were not generally powered to detect a difference within this subgroup.</p><p>Fixed-duration therapies are more intensive regimens administered for a set time period, followed by a treatment-free period. When compared with other CLL/SLL subgroups, this subgroup is likely to experience a longer treatment-free, and therefore toxicity-free, period following fixed-duration therapy. Those with progression after a prolonged response can be retreated with a second course.</p><p><a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> is administered for one year. While follow-up of trials investigating this approach are short, the vast majority of patients will remain off therapy for at least three years [<a href="#rid4">4</a>]. (See <a class="local">'Venetoclax plus obinutuzumab'</a> below.)</p><p><a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> is administered for 15 months. It is approved for this indication in Europe but not the United States. While follow-up is short, the vast majority of patients will remain off therapy for at least 2.5 years [<a href="#rid5">5</a>]. (See <a class="local">'Ibrutinib plus venetoclax'</a> below.)</p><p>Continuous therapy with a BTK inhibitor results in prolonged disease control in this population. <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">Acalabrutinib</a> and <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> are preferred over <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> because extrapolation of data from the relapsed setting suggests that they are at least as effective and better tolerated. These two agents have not been compared directly. However, in our practice, if the goal is best efficacy with acceptable toxicity, we offer zanubrutinib. In contrast, if the goal is best tolerability with good efficacy, we offer acalabrutinib. The addition of <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> to acalabrutinib appears to increase efficacy and increases toxicity with higher rates of cytopenias and infections. As such, we reserve acalabrutinib plus obinutuzumab for young/fit patients without a history of infection. Ibrutinib plus obinutuzumab has not been compared directly with ibrutinib alone. (See <a class="local">'Choice of Bruton tyrosine kinase inhibitor'</a> below and <a class="local">'Acalabrutinib'</a> below and <a class="local">'Zanubrutinib'</a> below.)</p><p>Long-term follow-up of prospective trials have demonstrated that a subset of patients with IGHV-mutated CLL treated with <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> obtain prolonged durable remissions [<a href="#rid6">6-9</a>]. However, if fixed-duration therapy is desired, targeted combinations such as <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> or <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus venetoclax are preferred to chemoimmunotherapy since this approach avoids the potential long-term toxicities of cytotoxic chemotherapy (eg, risk of secondary myelodysplastic syndrome and acute myeloid leukemia), and randomized trials have not demonstrated superiority of fludarabine, cyclophosphamide, and rituximab in this population.</p><p class="headingAnchor" id="H2926137583"><span class="h2">Infectious complications and prophylactic antimicrobials</span><span class="headingEndMark"> — </span>All patients with CLL/SLL are at an increased risk for infections. Pathogens of concern vary depending on the treatment regimen used. The use of prophylactic antimicrobials depends on the planned treatment regimen and its associated immune dysfunction. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia"</a> and  <a class="medical medical_review" href="/d/html/1405.html" rel="external">"Prevention of infections in patients with chronic lymphocytic leukemia"</a>.)</p><p class="headingAnchor" id="H2165425099"><span class="h1">BRUTON TYROSINE KINASE INHIBITORS</span></p><p class="headingAnchor" id="H426395029"><span class="h2">Choice of Bruton tyrosine kinase inhibitor</span><span class="headingEndMark"> — </span>The selection of a Bruton tyrosine kinase (BTK) inhibitor (<a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a>, <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a>, <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a>) is individualized based on available agents, comorbidities, and goals of therapy. All three BTK inhibitors are approved in the United States and Europe.</p><p>For most patients, we suggest <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> or <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> rather than <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a>. While we have the most experience and longest follow-up with ibrutinib, extrapolation of data from the relapsed setting suggests that acalabrutinib and zanubrutinib are at least as effective and better tolerated than ibrutinib. If both are available, the choice depends on individual treatment goals and a desire to balance efficacy and tolerability. These two agents have not been compared directly. However, in our practice, if the goal is best efficacy with acceptable tolerability, we offer zanubrutinib. In contrast, if the goal is best tolerability with acceptable efficacy, we offer acalabrutinib.</p><p>When compared with <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> in the relapsed setting, single-agent <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> has similar efficacy and an overall better tolerability profile (eg, fewer class-associated adverse effects, including cardiac toxicity, atrial fibrillation, hypertension, arthralgia, and bleeding) [<a href="#rid10">10</a>]. Efficacy can be improved with the addition of <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a>, although at a cost of increased toxicity [<a href="#rid11">11,12</a>]. (See  <a class="medical medical_review" href="/d/html/4520.html" rel="external">"Treatment of relapsed or refractory chronic lymphocytic leukemia", section on 'Acalabrutinib'</a> and <a class="local">'Acalabrutinib'</a> below.)</p><p>The improvement in tolerability is more narrow for <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> (ie, less cardiac toxicity, in particular less atrial fibrillation, but similar rates of other toxicities) [<a href="#rid13">13</a>]; however, zanubrutinib appears to be more effective than <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> in the relapsed setting with deeper responses and improved progression-free survival (PFS). (See  <a class="medical medical_review" href="/d/html/4520.html" rel="external">"Treatment of relapsed or refractory chronic lymphocytic leukemia", section on 'Zanubrutinib'</a> and <a class="local">'Zanubrutinib'</a> below.)</p><p>Experience with <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> and <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> is relatively short, and <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> remains a reasonable alternative for select patients despite an increased risk for atrial fibrillation, hypertension, bleeding, and arthralgias. (See <a class="local">'Ibrutinib'</a> below.)</p><p class="headingAnchor" id="H1211224032"><span class="h2">Acalabrutinib</span></p><p class="headingAnchor" id="H1835958437"><span class="h3">Administration and toxicity</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">Acalabrutinib</a> is one of our preferred initial therapies for CLL/SLL  (<a class="graphic graphic_algorithm graphicRef122052" href="/d/graphic/122052.html" rel="external">algorithm 1</a>). It is administered by mouth at a dose of 100 mg twice daily and continued until disease progression or unacceptable toxicity.</p><p><a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">Acalabrutinib</a> can be used as a single agent or in combination with <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a>. Single-agent acalabrutinib can be used for patients of all ages. The addition of obinutuzumab appears to increase efficacy and increases toxicity with higher rates of cytopenias and infections. As such, we reserve this combination for young/fit patients without a history of infection. (See <a class="local">'Efficacy of acalabrutinib'</a> below.)</p><p><a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">Acalabrutinib</a> has several drug interactions that may necessitate avoidance or dose adjustments. As an example, acalabrutinib and other BTK inhibitors are generally avoided in patients on anticoagulation, especially <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>. For detailed information on potential drug-drug interactions, refer to the <a class="external" href="/drug-interactions/">drug interactions program</a> within UpToDate. Acalabrutinib should also be avoided in patients with severe liver impairment.</p><p>The most common toxicities include anemia, neutropenia, thrombocytopenia, headache, upper respiratory tract infection, and diarrhea. Serious, potentially life-threatening toxicities include opportunistic infections, bleeding, arrhythmias, and second primary malignancies.</p><p>As such, <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> and other BTK inhibitors are generally avoided in patients with cardiovascular disorders, uncontrolled hypertension, and/or a high risk for bleeding (eg, history of major bleeding).</p><p>We advise holding <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> for three to seven days before and after surgery to mitigate the risk of perioperative bleeding. Platelet transfusions may lessen bleeding risk if urgent surgery cannot be delayed.</p><p>A rise in the lymphocyte count is expected after beginning therapy and should not be considered a sign of progressive disease in the absence of other features of progression. The lymphocyte count increases dramatically within 24 hours of starting a BTK inhibitor, peaks after one to two months, and then slowly resolves within eight months in most patients.</p><p class="headingAnchor" id="H1423838360"><span class="h3">Efficacy of acalabrutinib</span><span class="headingEndMark"> — </span>In the treatment-naïve setting, <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> improves PFS when compared with <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a>. Acalabrutinib has not been directly compared with other targeted therapies as initial therapy; however, extrapolation of data from the relapsed setting suggests that acalabrutinib has similar efficacy to <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> but an overall better tolerability profile, including less cardiotoxicity [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/4520.html" rel="external">"Treatment of relapsed or refractory chronic lymphocytic leukemia", section on 'Acalabrutinib'</a>.)</p><p>In a multicenter phase 3 trial (ELEVATE-TN), 535 older or frail adults with treatment-naïve CLL were randomly assigned 1:1:1 to receive six cycles of <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> followed by single-agent acalabrutinib, single-agent acalabrutinib alone, or six cycles of <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a> plus obinutuzumab [<a href="#rid11">11,14,15</a>]. Acalabrutinib was continued until progression or unacceptable toxicity.</p><p class="bulletIndent1"><span class="glyph">●</span>Progression-free survival – The estimated four-year PFS with <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> (87 percent) and acalabrutinib alone (78 percent) were higher than that seen with <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a> plus obinutuzumab (25 percent). Subgroup analyses included:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In immunoglobulin heavy chain variable (IGHV)-unmutated CLL/SLL, the estimated four-year PFS were 86, 77, and 4 percent, respectively.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In IGHV-mutated CLL/SLL, the estimated four-year PFS were 89, 81, and 62 percent, respectively.</p><p></p><p class="bulletIndent1">Among the 61 patients with 17p deletion or <em>TP53</em> mutation, the estimated five-year PFS in the two acalabrutinib-containing arms was 71 versus 18 percent with <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overall survival – Overall survival (OS) data are immature with estimated four-year OS of 93, 88, and 88 percent, respectively. OS may be impacted by the administration of <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> at the time of progression in a majority of patients on the <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> arm.</p><p></p><p>ELEVATE-TN was not designed to evaluate the impact of adding <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> to <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a>. On post-hoc analysis, the addition of obinutuzumab to acalabrutinib appears to improve PFS (hazard ratio [HR] 0.49; 95% CI 0.26-0.95) without an improvement in OS. On subgroup analyses, the improved efficacy with obinutuzumab was not demonstrated in patients with del(17p) or <em>TP53</em> mutation, although the confidence in these results is limited by a small sample size.</p><p>Among patients treated with single-agent <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> in ELEVATE-TN, the most common toxicities were infection (74 percent), bleeding (42 percent), diarrhea (40 percent), and headache (38 percent) [<a href="#rid11">11,14</a>]. Additional events of clinical interest included atrial fibrillation/flutter (4 percent), grade ≥3 hypertension (2.8 percent), and major bleeding (2.8 percent). The addition of <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> increased the rate of grade ≥3 toxicities (70 versus 50 percent), including neutropenia (31 versus 11 percent) and infection (24 versus 16 percent).</p><p class="headingAnchor" id="H569393713"><span class="h2">Zanubrutinib</span></p><p class="headingAnchor" id="H3369479817"><span class="h3">Administration and toxicity</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">Zanubrutinib</a> is one of our preferred initial therapies for CLL/SLL  (<a class="graphic graphic_algorithm graphicRef122052" href="/d/graphic/122052.html" rel="external">algorithm 1</a>). It is administered by mouth (either 160 mg twice daily or 320 mg once daily) and continued until disease progression or unacceptable toxicity.</p><p><a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">Zanubrutinib</a> has numerous drug interactions that may necessitate avoidance or dose adjustments. As an example, zanubrutinib and other BTK inhibitors are generally avoided in patients on anticoagulation, especially <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>. For more detailed information on potential drug-drug interactions, refer to the <a class="external" href="/drug-interactions/">drug interactions program</a> within UpToDate. Dose reductions are also needed for severe liver impairment.</p><p>The most common toxicities include bleeding, upper respiratory tract infection, diarrhea, arthralgias, and cardiac events. As such, <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> and other BTK inhibitors are generally avoided in patients with cardiovascular disorders, uncontrolled hypertension, and/or a high risk for bleeding (eg, history of major bleeding).</p><p>We advise holding <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> for three to seven days before and after surgery to mitigate the risk of perioperative bleeding. Platelet transfusions may lessen bleeding risk if urgent surgery cannot be delayed.</p><p>A rise in the lymphocyte count is expected after beginning therapy and should not be considered a sign of progressive disease in the absence of other features of progression. The lymphocyte count increases dramatically within 24 hours, peaks after one to two months, and then slowly resolves within eight months in most patients.</p><p class="headingAnchor" id="H3227323537"><span class="h3">Efficacy of zanubrutinib</span><span class="headingEndMark"> — </span>In the treatment-naïve setting, <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> improves PFS when compared with <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (BR). Zanubrutinib has not been directly compared with other targeted therapies as initial therapy; however, when compared with <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> in the relapsed setting, zanubrutinib improves PFS and has less cardiac toxicity, in particular less atrial fibrillation, but similar rates of other toxicities [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/4520.html" rel="external">"Treatment of relapsed or refractory chronic lymphocytic leukemia", section on 'Zanubrutinib'</a>.)</p><p>A multicenter, open-label, phase 3 trial (SEQUOIA) enrolled 590 adults with previously untreated CLL/SLL who were aged 65 years or older or had comorbidities [<a href="#rid16">16</a>]. The 479 patients without del(17p) were randomly assigned to receive <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> (at a dose of 160 mg twice daily) or six cycles of <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>. The 111 patients with del(17p) were assigned to receive zanubrutinib on a separate study arm. Testing for <em>TP53</em> mutation was not required. After a median follow-up of 26 months, the following were reported:</p><p class="bulletIndent1"><span class="glyph">●</span>Progression-free survival – Among those without del(17p), <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> improved PFS over that seen with <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (estimated two-year PFS 86 versus 70 percent; HR 0.42; 95% CI 0.28-0.63). A PFS benefit with zanubrutinib was seen in most predefined subgroups except in patients with mutated IGHV. Subgroup analysis was limited by a small sample size in those with SLL presentation or <em>TP53</em> mutation.</p><p></p><p class="bulletIndent1">Those with del(17p) treated with <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> had an estimated 18-month PFS of 89 percent [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overall survival – OS data are immature with &lt;10 percent deaths in each arm. Among those without del(17p), OS with <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> and <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> were similar (estimated two-year OS 94 versus 95 percent; HR 1.07; 95% CI 0.51-2.22).</p><p></p><p>Among patients treated with <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> in SEQUOIA, the most common toxicities were bleeding (44 percent), upper respiratory tract infection (17 percent), diarrhea (14 percent), arthralgia (14 percent), and cardiac events (14 percent) [<a href="#rid16">16</a>]. Additional events of clinical interest included atrial fibrillation (3 percent), grade ≥3 hypertension (6 percent), and major bleeding (5 percent). When compared with chemotherapy, zanubrutinib was less likely to require dose reduction or treatment discontinuation due to toxicity.</p><p class="headingAnchor" id="H3402923718"><span class="h2">Ibrutinib</span></p><p class="headingAnchor" id="H4002132482"><span class="h3">Administration and toxicity</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> is a highly effective treatment for CLL/SLL. However, if a BTK inhibitor is selected for initial therapy, we prefer <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> or <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> rather than ibrutinib, as they appear to be at least as effective and better tolerated  (<a class="graphic graphic_algorithm graphicRef122052" href="/d/graphic/122052.html" rel="external">algorithm 1</a>). (See <a class="local">'Choice of Bruton tyrosine kinase inhibitor'</a> above.)</p><p><a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> can be used as a single agent or in combination with <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a>. Single-agent ibrutinib can be used for patients of all ages. Ibrutinib plus obinutuzumab has not been compared directly versus ibrutinib alone and is expected to have increased toxicity, including higher rates of cytopenias and infections. As such, we reserve this combination for young/fit patients without a history of infection. Most experts do not add <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>; while it may shorten time to response, benefits in PFS or OS have not been demonstrated [<a href="#rid18">18,19</a>].</p><p>Single-agent <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> is administered by mouth at a dose of 420 mg once daily and continued until disease progression or unacceptable toxicity. Dose adjustments are needed for liver impairment. Most experts do not add <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>; while the addition of rituximab may shorten time to response, benefits in PFS or OS have not been demonstrated [<a href="#rid18">18,19</a>]. The combination of ibrutinib plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> is discussed separately. (See <a class="local">'Venetoclax plus obinutuzumab'</a> below.)</p><p><a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> has numerous drug interactions that may necessitate avoidance or dose adjustments. For more detailed information on potential drug-drug interactions, refer to the <a class="external" href="/drug-interactions/">drug interactions program</a> within UpToDate.</p><p>Toxicity with <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> is greatest during the first six cycles of treatment [<a href="#rid20">20</a>]. After six cycles, patients experience cumulative toxicity, although at a lower rate. Common toxicities include infection, bleeding, diarrhea, and headache. Additional toxicities of clinical interest include arrythmias, hypertension, infections, and bleeding. Pneumonitis and second primary malignancies are uncommon toxicities of ibrutinib [<a href="#rid21">21,22</a>]. Rare cases of hemophagocytic lymphohistiocytosis have been reported after exposure to ibrutinib [<a href="#rid23">23</a>].</p><p>Because of these toxicities, <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> and other BTK inhibitors are generally avoided in patients with cardiovascular disorders, uncontrolled hypertension, and/or a high risk for bleeding (eg, history of major bleeding). (See  <a class="medical medical_review" href="/d/html/2812.html" rel="external">"Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines", section on 'BTK inhibitors'</a>.)</p><p>We advise holding <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> for three to seven days before and after surgery to mitigate the risk of perioperative bleeding. Platelet transfusions may lessen bleeding risk if urgent surgery cannot be delayed.</p><p>A rise in the lymphocyte count is expected after beginning therapy and should not be considered a sign of progressive disease in the absence of other features of progression. The lymphocyte count increases dramatically within 24 hours of starting a BTK inhibitor, peaks after one to two months, and then slowly resolves within eight months in most patients [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H276916441"><span class="h3">Efficacy of ibrutinib</span><span class="headingEndMark"> — </span>Multiple randomized trials have compared ibrutinib-based therapy versus various chemotherapy regimens in older and younger adults with CLL/SLL. All have demonstrated improved PFS, while some have demonstrated improved OS. In subgroup analyses, the improvement in PFS seen in the general population is of lesser magnitude and does not always reach statistical significance in patients with IGHV-mutated CLL. <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> has not been directly compared with other targeted therapies for the initial treatment of CLL/SLL.</p><p>Very few patients with del(17p) or <em>TP53</em> mutation were included in the studies below. Additional experience in this group comes from small single-arm trials [<a href="#rid19">19,25-29</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ibrutinib</strong><strong> plus </strong><strong>rituximab</strong><strong> versus </strong><strong>fludarabine</strong><strong>, </strong><strong>cyclophosphamide</strong><strong>, and </strong><strong>rituximab</strong> – Two randomized phase 3 trials (ECOG-ACRIN E1912 [<a href="#rid30">30,31</a>] and FLAIR [<a href="#rid32">32</a>]) compared <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> versus six cycles of <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and rituximab in a combined 1300 patients with previously untreated CLL.</p><p></p><p class="bulletIndent1">In both trials, <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> improved PFS (HR 0.37 and 0.44). In ECOG-ACRIN E1912, a PFS benefit was seen in both IGHV-unmutated CLL/SLL (75 versus 33 percent at five years; HR 0.27; 95% CI 0.18-0.41) and IGHV-mutated CLL/SLL (83 versus 68 percent at five years; HR 0.27; 95% CI 0.11-0.62). In FLAIR, the PFS benefit was seen in IGHV-unmutated CLL (HR 0.41) but did not reach statistical significance for IGHV-mutated CLL.</p><p></p><p class="bulletIndent1">In ECOG-ACRIN E1912, <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> also improved OS (95 versus 89 percent at five years; HR 0.47; 95% CI 0.25-0.89) in the population as a whole and in IGHV-unmutated CLL/SLL (HR 0.35; 95% CI 0.15-0.80) but not in IGHV-mutated CLL/SLL (HR 0.72; 95% CI 0.15-3.47). In FLAIR, an OS benefit was not seen (HR 1.01).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ibrutinib</strong><strong> versus </strong><strong>ibrutinib</strong><strong> plus </strong><strong>rituximab</strong><strong> versus </strong><strong>bendamustine</strong><strong> plus </strong><strong>rituximab</strong> – A randomized phase 3 trial (Alliance A041202) compared single-agent <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> versus ibrutinib plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> versus six cycles of <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus rituximab in 547 older adults with previously untreated CLL [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1">Single-agent <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> improved PFS over that seen with <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (estimated two-year PFS 87 versus 74 percent; HR 0.39; 95% CI 0.26-0.58). On subgroup analysis, this benefit was seen in those with or without del17p; however, the benefit lost statistical significance among those with methylated ZAP-70 (a marker that is strongly associated with the presence of mutated IGHV). The addition of rituximab to ibrutinib increased complete response rates (12 versus 26 percent) but not PFS (HR 1.00; 95% CI 0.62-1.62).</p><p></p><p class="bulletIndent1">OS data are immature, but there is no hint for a difference in the full population as of yet, although this study allowed crossover, which limits the ability to detect an OS advantage.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ibrutinib</strong><strong> plus </strong><strong>obinutuzumab</strong><strong> versus </strong><strong>chlorambucil</strong><strong> plus </strong><strong>obinutuzumab</strong> – A randomized phase 3 trial (iLLUMINATE) compared <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> versus <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a> plus obinutuzumab in 229 mostly older adults with previously untreated CLL [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> prolonged PFS (30-month PFS 79 versus 31 percent; HR 0.23; 95% CI 0.15-0.37). The estimated 30-month OS was similar between the arms (86 versus 85 percent), although crossover was allowed upon progression.</p><p></p><p class="bulletIndent1">The study design does not allow for a direct assessment of the impact of <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> in the combination. Among those treated with <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus obinutuzumab, the rate of complete response (19 percent) and undetectable measurable residual disease (35 percent) compare favorably with those seen with single-agent ibrutinib in other trials.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ibrutinib</strong><strong> versus </strong><strong>chlorambucil</strong> – A randomized phase 3 trial (RESONATE-2) compared single-agent <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> versus up to 12 cycles of <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a> in 269 older adults with previously untreated CLL [<a href="#rid34">34-37</a>]. Ibrutinib improved PFS (seven-year PFS 59 versus 9 percent; HR 0.15; 95% CI 0.10-0.22). On subgroup analysis, this benefit was seen across all subgroups, including those with and without del17p and/or del(11q) and in those with mutated IGHV and unmutated IGHV. Ibrutinib also improved OS (five-year OS 83 versus 68 percent; HR 0.45; 95% CI 0.28-0.74).</p><p></p><p class="headingAnchor" id="H1712453115"><span class="h1">VENETOCLAX PLUS OBINUTUZUMAB</span></p><p class="headingAnchor" id="H3781894708"><span class="h2">Administration and toxicity</span><span class="headingEndMark"> — </span>Fixed-duration <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> is one of our preferred initial therapies for CLL/SLL  (<a class="graphic graphic_algorithm graphicRef122052" href="/d/graphic/122052.html" rel="external">algorithm 1</a>). It is particularly useful for patients who are poor candidates for a Bruton tyrosine kinase (BTK) inhibitor due to comorbidities (eg, atrial fibrillation, history of severe bleeding) or concomitant medications (eg, anticoagulants). (See <a class="local">'Choice of therapy'</a> above.)</p><p>The most common toxicities with <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> are neutropenia, thrombocytopenia, anemia, diarrhea, nausea, upper respiratory tract infection, cough, musculoskeletal pain, fatigue, and edema. When administered according to the schedules used in the trials and with risk-based prophylaxis, tumor lysis syndrome (TLS) is rare.</p><p><a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> is administered over one year and followed by a treatment-free period. Those with progression after a prolonged response can be retreated with a second one-year course.</p><p>Treatment with <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> is logistically complicated and follows a strict dose escalation schedule that begins with several doses of obinutuzumab prior to initiation and dose escalation of venetoclax [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/d/html/4520.html" rel="external">"Treatment of relapsed or refractory chronic lymphocytic leukemia", section on 'BCL2 inhibitors: Venetoclax'</a>.) </p><p>Important specific considerations for <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> is avoided in patients with severe kidney impairment (creatinine clearance &lt;30 mL/min and patients on dialysis), those on nephrotoxic drugs, and those taking a strong CYP3A inhibitor, as these can increase the risk for TLS. For more detailed information on potential drug-drug interactions, refer to the <a class="external" href="/drug-interactions/">drug interactions program</a> within UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> can cause life-threatening TLS. All patients should receive TLS prophylaxis and be monitored to allow for the early detection of TLS. The specific prophylaxis measures used depend upon the patient's estimated risk of TLS, which differs according to tumor burden (lymph node size and absolute lymphocyte count), as described in more detail separately. (See  <a class="medical medical_review" href="/d/html/4520.html" rel="external">"Treatment of relapsed or refractory chronic lymphocytic leukemia", section on 'BCL2 inhibitors: Venetoclax'</a>.)</p><p></p><p><a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">Obinutuzumab</a> can be associated with infusion-related reactions, hepatitis B virus (HBV) reactivation, and other complications. The following administration considerations are of particular importance. For additional guidance, see the package instructions.</p><p class="bulletIndent1"><span class="glyph">●</span>Infusion reactions – Premedication is mandatory to minimize infusion reactions. This is described in more detail separately. (See  <a class="medical medical_review" href="/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Obinutuzumab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis B virus reactivation – All patients should be screened for HBV prior to starting treatment. Patients with evidence of prior HBV infection should be monitored for clinical and laboratory signs of reactivation during therapy and for several months after completion of therapy. This is described in more detail separately. (See  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunosuppression – Anti-CD20 monoclonal antibodies target B cells and can lead to secondary immunodeficiency. (See  <a class="medical medical_review" href="/d/html/3939.html" rel="external">"Secondary immunodeficiency induced by biologic therapies", section on 'Monoclonal antibodies to B cells'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Progressive multifocal leukoencephalopathy – There is a small but increased risk of progressive multifocal leukoencephalopathy (PML) with the use of anti-CD20 monoclonal antibodies. PML typically presents with subacute neurologic deficits, including altered mental status, visual symptoms, paralysis, and ataxia. (See  <a class="medical medical_review" href="/d/html/1694.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p>Rare cases of severe, sometimes fatal, disseminated intravascular coagulation (DIC) have been reported in patients treated with <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H3230783710"><span class="h2">Efficacy of venetoclax plus obinutuzumab</span><span class="headingEndMark"> — </span>Data supporting the use of <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> in previously untreated CLL come from two open-label phase 3 trials that evaluated this combination in young, fit patients (GAIA-CLL13 [<a href="#rid38">38</a>]) and those with significant comorbidities (CLL14 [<a href="#rid40">40,41</a>]). In both trials, venetoclax plus obinutuzumab deepened responses and improved progression-free survival (PFS) over that seen with chemoimmunotherapy.</p><p>In subgroup analyses, the improvement in PFS seen in the general population was of lesser magnitude and did not reach statistical significance in patients with immunoglobulin heavy chain variable (IGHV)-mutated CLL. Further follow-up is needed to assess the durability of remissions and impact on overall survival (OS), although most patients remain in remission for three years following the completion of therapy [<a href="#rid4">4</a>]. Very few patients with del(17p) or <em>TP53</em> mutation were included in the studies below. Additional experience in this group comes from small, single-arm trials [<a href="#rid42">42,43</a>]. <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> has not been directly compared with other targeted therapies for the initial treatment of CLL/SLL.</p><p>In the GAIA-CLL13 trial, 926 younger adults with minimal comorbidities and without 17p deletion or <em>TP53</em> mutation were randomly assigned to one of four time-limited therapies [<a href="#rid38">38</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> for 12 cycles</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> for 12 cycles</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> plus <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> for 12 cycles, followed by single-agent ibrutinib in those with detectable measurable residual disease (MRD; also called "minimal residual disease")</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chemoimmunotherapy with <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus rituximab for six cycles </p><p></p><p>Key outcomes included:</p><p class="bulletIndent1"><span class="glyph">●</span>When compared with chemoimmunotherapy, <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> improved PFS (three-year PFS 87.7 versus 75.5 percent) and achievement of undetectable MRD (uMRD) at 15 months (86.5 versus 52 percent). The addition of <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> resulted in a small incremental benefit in these outcomes (three-year PFS 90.5 percent, uMRD 92.2 percent) and an increase in grade 3 and 4 infection (21.2 versus 13.2 percent). Venetoclax plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> did not improve PFS or uMRD over that seen with chemoimmunotherapy. Data on OS are immature.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with unmutated IGHV, the three-year PFS was higher among patients treated with <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> (82.9 percent) and venetoclax, obinutuzumab, plus <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> (86.6 percent) versus chemoimmunotherapy (65.5 percent); PFS with venetoclax plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (76.4 percent) was not superior to chemoimmunotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with mutated IGHV, improvements in the three-year PFS were numerically higher in the obinutuzumab-containing arms but did not reach statistical significance: <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> (93.6 percent), venetoclax, obinutuzumab, plus <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> (96 percent), venetoclax plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (87 percent), and chemoimmunotherapy (89.9 percent).</p><p></p><p>In the CLL14 trial, 432 adults with previously untreated CLL and significant comorbidities were randomly assigned to <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> versus <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a> plus obinutuzumab, each given for a fixed duration of 12 months [<a href="#rid3">3,4,40,41,44,45</a>]. Key outcomes included:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> improved PFS, and most patients maintained remission for three years following the completion of venetoclax plus obinutuzumab (four-year PFS 74 versus 35 percent; hazard ratio [HR] 0.33; 95% CI 0.25-0.45). A PFS benefit was seen in patients with 17p deletion, <em>TP53</em> mutation, or both and in patients with complex karyotype or IGHV-unmutated CLL, but not among patients with IGHV-mutated CLL.</p><p></p><p class="bulletIndent1">In patients with unmutated IGHV, the two-year PFS was higher with <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> (two-year PFS 89.4 versus 51 percent).</p><p></p><p class="bulletIndent1">In patients with mutated IGHV, the two-year PFS was numerically higher with <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> but did not reach statistical significance (two-year PFS 90.3 versus 85.6 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>OS rates were similar in the two arms (87 versus 87 percent at 36 months; HR 1.03; 95% CI 0.60-1.75). The median OS has not been reached in either arm, or the survival data are immature.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rates of grade 3 or 4 toxicity were similar in the two arms (79 and 77 percent). In those receiving <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a>, grade 3 or 4 neutropenia and febrile neutropenia occurred in 53 and 5 percent, respectively. Growth factors could be administered at the discretion of the treating clinician. TLS was rare. Quality of life measures suggested that the use of venetoclax plus obinutuzumab did not impair quality of life and resulted in earlier relief of CLL-related symptoms [<a href="#rid45">45</a>].</p><p></p><p>Further support for <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> is extrapolated from studies in the relapsed setting where venetoclax plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> has demonstrated superior PFS and OS when compared with <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus rituximab. This is described in more detail separately. (See  <a class="medical medical_review" href="/d/html/4520.html" rel="external">"Treatment of relapsed or refractory chronic lymphocytic leukemia", section on 'BCL2 inhibitors: Venetoclax'</a>.)</p><p class="headingAnchor" id="H3169586019"><span class="h1">IBRUTINIB PLUS VENETOCLAX</span></p><p class="headingAnchor" id="H3266330354"><span class="h2">Clinical use</span><span class="headingEndMark"> — </span>Fixed-duration <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> is an option for the initial treatment of CLL/SLL and is approved for this indication in Europe but not the United States  (<a class="graphic graphic_algorithm graphicRef122052" href="/d/graphic/122052.html" rel="external">algorithm 1</a>). (See <a class="local">'Choice of therapy'</a> above.)</p><p><a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> is administered over 15 months and followed by a treatment-free period. Those with progression after a prolonged response can be retreated with a second course of ibrutinib plus venetoclax. Those with unacceptable toxicity may be candidates for continuous therapy with a Bruton tyrosine kinase (BTK) inhibitor or with time-limited venetoclax plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>. Fixed-duration ibrutinib plus venetoclax has not been directly compared with measurable residual disease (MRD)-guided ibrutinib plus venetoclax. MRD-guided treatment does not have regulatory approval, and it is not known whether using MRD assessments to extend the duration of therapy will improve outcomes. </p><p>While trials have studied other combinations of BTK inhibitors plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> with or without an anti-CD20 monoclonal antibody (eg, venetoclax, <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a>, and <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a>; venetoclax, obinutuzumab, and <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a>), use of these other combinations is considered investigational.</p><p class="headingAnchor" id="H2723394768"><span class="h2">Efficacy and toxicity</span><span class="headingEndMark"> — </span>The combination of a BTK inhibitor (<a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> or <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a>) plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> with or without an anti-CD20 monoclonal antibody results in deep responses with a sizeable percentage of patients achieving undetectable MRD (uMRD) [<a href="#rid46">46-57</a>]. Studies of ibrutinib plus venetoclax have demonstrated improved progression-free survival (PFS) and overall survival (OS) when compared with chemoimmunotherapy. The ibrutinib lead-in prior to starting venetoclax also appears to decrease the risk of tumor lysis syndrome (TLS).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fixed-duration</strong> <strong>ibrutinib</strong><strong> plus </strong><strong>venetoclax</strong> – An open-label, randomized phase 3 trial (GLOW) compared <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> versus <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> in 211 older or frail adults with previously untreated CLL without del(17p) or <em>TP53</em> mutation [<a href="#rid58">58,59</a>]. Ibrutinib was administered as a single agent for three cycles, followed by 12 cycles of ibrutinib plus venetoclax. Chlorambucil plus obinutuzumab was administered for six standard 28-day cycles. After a median follow-up of 46 months:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> improved PFS (3.5-year PFS 75 versus 25 percent; HR 0.21, 95% CI 0.14-0.33) and OS (3.5-year OS 88 versus 78 percent; HR 0.49, 95% CI 0.26-0.91). It resulted in deeper responses with a higher percentage of uMRD in the bone marrow at three months after the end of treatment by next-generation sequencing (52 versus 17 percent). The vast majority of patients treated with ibrutinib plus venetoclax did not require subsequent treatment at 3.5 years (94 percent of those with mutated immunoglobulin heavy chain variable [IGHV], 91 percent of those with unmutated IGHV; time to next therapy HR 0.16, 95% CI 0.07-0.33).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among the 26 patients who were at high risk of TLS at the start of <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> treatment, all but two converted to medium or low risk prior to starting <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The most common grade ≥3 treatment-emergent adverse events were neutropenia (35 percent), diarrhea (10 percent), and hypertension (8 percent) among those treated with <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a>, and neutropenia (50 percent), thrombocytopenia (20 percent), infections (11 percent), and TLS (6 percent) among those treated with <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">chlorambucil</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a>. There were nine treatment-related deaths. There were seven deaths in the ibrutinib plus venetoclax arm, with four deaths due to cardiac or sudden death.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MRD-guided </strong><strong>ibrutinib</strong><strong> plus </strong><strong>venetoclax</strong> – An open-label, randomized phase 3 trial (Flair) compared MRD-guided <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> versus <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (FCR) in 523 adults with previously untreated CLL without del(17p) [<a href="#rid60">60</a>]. Ibrutinib was given as a single agent for two cycles, followed by ibrutinib plus venetoclax administered for two to six years. The duration of combination therapy was double the time taken to achieve uMRD defined using repeat assessments of flow cytometry of the peripheral blood and bone marrow with a detection limit of 1x10<sup>-5</sup>. FCR was administered for six standard 28-day cycles. After a median follow-up of 44 months:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The percentage of patients who were able to discontinue <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> due to MRD stopping rules increased with time: 24 months (29 percent), 36 months (58 percent), and 60 months (78 percent). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> improved PFS (3-year PFS 97.2 versus 76.8 percent; HR 0.13, 95% CI 0.07-0.24) and OS (3-year OS 98 versus 93 percent; HR 0.31, 95% CI 0.15-0.67). On subgroup analysis, PFS benefit was more prominent in those with unmutated IGHV (3-year PFS 98 versus 71; HR 0.07, 95% CI 0.02-0.19) and did not reach statistical significance in those with mutated IGHV (3-year PFS 94 versus 89 percent; HR 0.54, 95% CI 0.21-1.38).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>FCR resulted in more cytopenias and secondary malignancies. <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> resulted in more cardiac toxicity (eg, serious cardiac events 11 versus 0.4 percent). There were seven deaths attributed to treatment: six in the FCR arm (infections, secondary cancers, and sudden unexplained or cardiac death), and one in the ibrutinib plus venetoclax arm (sudden unexplained or cardiac death). </p><p></p><p class="bulletIndent1">Fixed-duration <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> has not been directly compared with MRD-guided ibrutinib plus venetoclax. MRD-guided treatment does not have regulatory approval, and it is not known whether using MRD assessments to extend the duration of therapy will improve outcomes. In particular, patients with mutated IGHV were less likely to achieve MRD negativity in all ibrutinib plus venetoclax datasets but still have superior PFS as compared to those with unmutated IGHV. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ibrutinib</strong><strong>, </strong><strong>venetoclax</strong><strong>, and </strong><strong>obinutuzumab</strong> – An open-label, randomized phase 3 trial (GAIA-CLL13) compared the following time-limited therapies in 926 young, fit patients without 17p deletion or <em>TP53</em> mutation [<a href="#rid38">38</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">Venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> plus <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a></p><p class="bulletIndent2"><span class="glyph">•</span>Chemoimmunotherapy with FCR or <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a></p><p></p><p class="bulletIndent1">Key outcomes included:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When compared with chemoimmunotherapy, <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> plus <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> improved PFS (three-year PFS 90.5 versus 75.5 percent) and achievement of uMRD at 15 months (92.2 versus 52 percent). When compared with venetoclax plus obinutuzumab alone, there was a small incremental benefit in these outcomes (three-year PFS 90.5 versus 87.7 percent, uMRD 92.2 versus 86.5 percent) and an increase in grade 3 and 4 infection (21.2 versus 13.2 percent). Data on OS are immature.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with unmutated IGHV, the three-year PFS was higher among patients treated with <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> (82.9 percent) and venetoclax, obinutuzumab, plus <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> (86.6 percent) versus chemoimmunotherapy (65.5 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with mutated IGHV, improvements in PFS were numerically higher in the obinutuzumab-containing arms but did not reach statistical significance: <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> (93.6 percent), venetoclax, obinutuzumab, plus <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> (96 percent), venetoclax plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (87 percent), and chemoimmunotherapy (89.9 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acalabrutinib</strong><strong>, </strong><strong>venetoclax</strong><strong>, </strong><strong>obinutuzumab</strong> – In a phase 2 trial, the combination of <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a>, <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a>, and <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> resulted in complete remission with uMRD in the bone marrow in 14 of 37 (38 percent) patients with previously untreated CLL by the start of cycle 16 [<a href="#rid52">52</a>].</p><p></p><p class="headingAnchor" id="H1237287022"><span class="h1">CHEMOIMMUNOTHERAPY</span><span class="headingEndMark"> — </span>Chemoimmunotherapy was widely used for the treatment of CLL/SLL prior to the development of targeted therapies. However, targeted therapies are preferred over chemoimmunotherapy in all patients with CLL/SLL given their efficacy and superior side effect profiles. Chemotherapy may be considered in resource-limited settings without access to targeted therapies. Chemoimmunotherapy is <strong>not</strong> appropriate for patients with CLL/SLL with del(17p) and/or <em>TP53</em> mutation and much less efficacious in patients with unmutated immunoglobulin heavy chain variable.</p><p>If chemoimmunotherapy is chosen, the preferred regimen depends on clinical fitness [<a href="#rid61">61</a>]. In order of decreasing efficacy and increasing tolerability, options include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">Fludarabine</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">Bendamustine</a> plus <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">Chlorambucil</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a></p><p></p><p>Studies comparing these regimens to targeted therapies are described in the sections above.</p><p class="headingAnchor" id="H3238258712"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120614.html" rel="external">"Society guideline links: Chronic lymphocytic leukemia/small lymphocytic lymphoma"</a>.)</p><p class="headingAnchor" id="H1501229340"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/687.html" rel="external">"Patient education: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/686.html" rel="external">"Patient education: Hematopoietic cell transplantation (bone marrow transplantation) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H5623578"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for treatment</strong> – Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is an extremely heterogeneous disease. Most patients do not require treatment at the time of diagnosis. Therapy is indicated for patients with disease-related complications, termed "active disease" by the International Workshop on CLL (iwCLL)  (<a class="graphic graphic_table graphicRef96185" href="/d/graphic/96185.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/4545.html" rel="external">"Overview of the treatment of chronic lymphocytic leukemia", section on 'Indications for treatment ("active disease")'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment evaluation</strong> – A pretreatment evaluation is performed to determine the extent of disease, patient comorbidities, medications, and tumor genetic features (eg, 17p deletion, <em>TP53</em> mutation, immunoglobulin heavy chain variable [IGHV] mutation) that impact treatment. (See <a class="local">'Pretreatment evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of therapy and prognosis</strong> – Patients with CLL/SLL are not cured with conventional therapy. Treatment alleviates symptoms, reverses cytopenias, and is given with the overall goals of improving quality of life and prolonging overall survival. (See <a class="local">'Goals of therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assess comorbidities and patient preference</strong> – The treatments used for CLL/SLL differ significantly in associated toxicities and burden of administration. As such, comorbidities, concomitant medications, logistics, and patient preferences weigh substantially in the final treatment decision  (<a class="graphic graphic_table graphicRef142941" href="/d/graphic/142941.html" rel="external">table 3</a>). (See <a class="local">'Assess comorbidities and patient preferences'</a> above.)</p><p></p><p class="bulletIndent1">The main treatment options are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Continuous therapy with a Bruton tyrosine kinase (BTK) inhibitor, either <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> or <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a></p><p class="bulletIndent2"><span class="glyph">•</span>Fixed-duration <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic risk stratification</strong> – Our preferred initial therapy depends on a genetic risk stratification of the tumor  (<a class="graphic graphic_algorithm graphicRef122052" href="/d/graphic/122052.html" rel="external">algorithm 1</a>) and is then adjusted for comorbidities and patient preference:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>17p deletion and/or </strong><strong><em>TP53</em></strong><strong> mutation</strong> – For most patients with del(17p) or <em>TP53</em> mutation, we suggest continuous therapy with a BTK inhibitor rather than fixed-duration <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> or <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus venetoclax (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>)  (<a class="graphic graphic_algorithm graphicRef122052" href="/d/graphic/122052.html" rel="external">algorithm 1</a>). (See <a class="local">'Del(17p) and/or TP53 mutations (very high risk)'</a> above.)</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">Acalabrutinib</a> and <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> appear to be at least as effective and better tolerated than <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a>. These two agents have not been compared directly. However, in our practice, if the goal is best efficacy with acceptable toxicity, we offer zanubrutinib. In contrast, if the goal is best tolerability with good efficacy, we offer acalabrutinib. (See <a class="local">'Choice of Bruton tyrosine kinase inhibitor'</a> above and <a class="local">'Acalabrutinib'</a> above and <a class="local">'Zanubrutinib'</a> above.)</p><p></p><p class="bulletIndent2">Fixed-duration <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> or <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus venetoclax are acceptable alternatives. Venetoclax plus obinutuzumab may be preferred in patients who are poor candidates for a BTK inhibitor due to comorbidities (eg, history of atrial fibrillation, moderate hepatic impairment, history of severe bleeding) or concomitant medications (eg, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>). (See <a class="local">'Venetoclax plus obinutuzumab'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunoglobulin heavy chain variable unmutated (without 17p deletion or </strong><strong><em>TP53</em></strong><strong> mutation)</strong> – Patients with IGHV-unmutated CLL and without del(17p) or <em>TP53</em> mutation may reasonably choose continuous therapy with <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> or <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> or fixed-duration <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> or <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus venetoclax depending upon comorbidities, concomitant medications, patient preference, and logistics. These options have not been directly compared in randomized trials, but all have shown improved progression-free survival when compared with chemoimmunotherapy in this population. (See <a class="local">'Immunoglobulin heavy chain variable unmutated (high risk)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunoglobulin heavy chain variable mutated (without 17p deletion or </strong><strong><em>TP53</em></strong><strong> mutation)</strong> – For most patients with IGHV-mutated CLL and without del(17p) or <em>TP53</em> mutation, we suggest fixed-duration therapy with <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a> plus <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a> or <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a> plus venetoclax rather than continuous therapy with a BTK inhibitor (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). This approach is likely to offer a prolonged treatment-free period in this population. Continuous therapy with <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a> or <a class="drug drug_general" data-topicid="126183" href="/d/drug information/126183.html" rel="external">zanubrutinib</a> are reasonable alternatives, especially for those who are poor candidates for venetoclax plus obinutuzumab due to kidney impairment, use of nephrotoxic drugs, and/or a strong CYP3A inhibitor. (See <a class="local">'Immunoglobulin heavy chain variable mutated (standard risk)'</a> above.)</p><p></p><p class="headingAnchor" id="H1028060"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael J Keating, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018; 131:2745.</a></li><li><a class="nounderline abstract_t">Blum KA, Young D, Broering S, et al. Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria. J Clin Oncol 2007; 25:5624.</a></li><li><a class="nounderline abstract_t">Tausch E, Schneider C, Robrecht S, et al. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood 2020; 135:2402.</a></li><li><a class="nounderline abstract_t">Al-Sawaf O, Zhang C, Lu T, et al. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. J Clin Oncol 2021; 39:4049.</a></li><li><a class="nounderline abstract_t">Niemann CU, Munir T, Moreno C, et al. Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib plus Venetoclax (Ibr+Ven) versus Chlorambucil plus Obinutuzumab (Clb+O): the GLOW Study (abstract). Blood 2022; 140:228.</a></li><li><a class="nounderline abstract_t">Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112:975.</a></li><li><a class="nounderline abstract_t">Strati P, Wierda W, Burger J, et al. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. Cancer 2013; 119:3805.</a></li><li><a class="nounderline abstract_t">Thompson PA, Tam CS, O'Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 2016; 127:303.</a></li><li><a class="nounderline abstract_t">Thompson PA, Bazinet A, Wierda WG, et al. Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up. Blood 2023; 142:1784.</a></li><li><a class="nounderline abstract_t">Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J Clin Oncol 2021; 39:3441.</a></li><li><a class="nounderline abstract_t">Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 2020; 395:1278.</a></li><li><a class="nounderline abstract_t">Sharman J, Egyed M, Jurczak W, et al. Acalabrutinib +/- obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: ELEVATE-TN 4-year follow-up (abstract S148). Hemasphere 2021.</a></li><li><a class="nounderline abstract_t">Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 2023; 388:319.</a></li><li><a class="nounderline abstract_t">Sharman JP, Egyed M, Jurczak W, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia 2022; 36:1171.</a></li><li class="breakAll">Acalabrutinib +/- obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 5-year follow-up of ELEVATE-TN. Presented at European Hematology Association Annual Meedint 2022, abstract P666. https://library.ehaweb.org/eha/2022/eha2022-congress/357528/jeff.p.sharman.acalabrutinib.obinutuzumab.vs.obinutuzumab.2B.chlorambucil.in.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dp666 (Accessed on May 13, 2023).</li><li><a class="nounderline abstract_t">Tam CS, Brown JR, Kahl BS, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol 2022; 23:1031.</a></li><li><a class="nounderline abstract_t">Tam CS, Robak T, Ghia P, et al. Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion. Haematologica 2020; 106:2354.</a></li><li><a class="nounderline abstract_t">Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 2018; 379:2517.</a></li><li><a class="nounderline abstract_t">Burger JA, Sivina M, Jain N, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 2019; 133:1011.</a></li><li><a class="nounderline abstract_t">Ruppert AS, Booth AM, Ding W, et al. Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia 2021; 35:2854.</a></li><li><a class="nounderline abstract_t">Mato AR, Islam P, Daniel C, et al. Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia. Blood 2016; 127:1064.</a></li><li><a class="nounderline abstract_t">Bond DA, Huang Y, Fisher JL, et al. Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia 2020; 34:3197.</a></li><li><a class="nounderline abstract_t">Ambinder AJ, Hambley B, Shanbhag S, Merrill SA. Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins. Am J Hematol 2019; 94:E296.</a></li><li><a class="nounderline abstract_t">Herman SE, Niemann CU, Farooqui M, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia 2014; 28:2188.</a></li><li><a class="nounderline abstract_t">Farooqui MZ, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 2015; 16:169.</a></li><li><a class="nounderline abstract_t">Ahn IE, Farooqui MZH, Tian X, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood 2018; 131:2357.</a></li><li><a class="nounderline abstract_t">Ahn IE, Tian X, Wiestner A. Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations. N Engl J Med 2020; 383:498.</a></li><li><a class="nounderline abstract_t">Cramer P, Tausch E, von Tresckow J, et al. Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations. Blood 2021; 138:1805.</a></li><li><a class="nounderline abstract_t">Sivina M, Kim E, Wierda WG, et al. Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations. Blood 2021; 138:2589.</a></li><li><a class="nounderline abstract_t">Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med 2019; 381:432.</a></li><li><a class="nounderline abstract_t">Shanafelt TD, Wang XV, Hanson CA, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood 2022; 140:112.</a></li><li><a class="nounderline abstract_t">Hillmen P, Pitchford A, Bloor A, et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2023; 24:535.</a></li><li><a class="nounderline abstract_t">Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20:43.</a></li><li><a class="nounderline abstract_t">Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 2020; 34:787.</a></li><li><a class="nounderline abstract_t">Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med 2015; 373:2425.</a></li><li><a class="nounderline abstract_t">Barr PM, Robak T, Owen C, et al. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica 2018; 103:1502.</a></li><li><a class="nounderline abstract_t">Barr PM, Owen C, Robak T, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv 2022; 6:3440.</a></li><li><a class="nounderline abstract_t">Eichhorst B, Niemann CU, Kater AP, et al. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. N Engl J Med 2023; 388:1739.</a></li><li class="breakAll">Obinutuzumab injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125486s033lbl.pdf (Accessed on July 20, 2022).</li><li><a class="nounderline abstract_t">Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med 2019; 380:2225.</a></li><li><a class="nounderline abstract_t">Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2020; 21:1188.</a></li><li><a class="nounderline abstract_t">Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 2016; 17:768.</a></li><li><a class="nounderline abstract_t">Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol 2018; 36:1973.</a></li><li><a class="nounderline abstract_t">Al-Sawaf O, Lilienweiss E, Bahlo J, et al. High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. Blood 2020; 135:866.</a></li><li><a class="nounderline abstract_t">Al-Sawaf O, Gentile B, Devine J, et al. Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial. Am J Hematol 2021; 96:1112.</a></li><li><a class="nounderline abstract_t">Jain N, Keating M, Thompson P, et al. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 2019; 380:2095.</a></li><li><a class="nounderline abstract_t">Hillmen P, Rawstron AC, Brock K, et al. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. J Clin Oncol 2019; 37:2722.</a></li><li><a class="nounderline abstract_t">Kater AP, Levin MD, Niemann CU. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 2019; 381:788.</a></li><li><a class="nounderline abstract_t">Rogers KA, Huang Y, Ruppert AS, et al. Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol 2020; 38:3626.</a></li><li><a class="nounderline abstract_t">Niemann CU, Levin MD, Dubois J, et al. Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia. Blood 2021; 137:1117.</a></li><li><a class="nounderline abstract_t">Jain N, Keating M, Thompson P, et al. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 2021; 7:1213.</a></li><li><a class="nounderline abstract_t">Davids MS, Lampson BL, Tyekucheva S, et al. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol 2021; 22:1391.</a></li><li><a class="nounderline abstract_t">Wierda WG, Allan JN, Siddiqi T, et al. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol 2021; 39:3853.</a></li><li><a class="nounderline abstract_t">Tam CS, Allan JN, Siddiqi T, et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood 2022; 139:3278.</a></li><li><a class="nounderline abstract_t">Huber H, Edenhofer S, von Tresckow J, et al. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. Blood 2022; 139:1318.</a></li><li><a class="nounderline abstract_t">Kater AP, Levin MD, Dubois J, et al. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial. Lancet Oncol 2022; 23:818.</a></li><li><a class="nounderline abstract_t">Huber H, Tausch E, Schneider C, et al. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut. Blood 2023; 142:961.</a></li><li><a class="nounderline abstract_t">Kater AP, Owen C, Moreno C, et al. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. NEJM Evid 2022; 1.</a></li><li><a class="nounderline abstract_t">Niemann CU, Munir T, Moreno C, et al. Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2023; 24:1423.</a></li><li><a class="nounderline abstract_t">Munir T, Cairns DA, Bloor A, et al. Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. N Engl J Med 2023.</a></li><li><a class="nounderline abstract_t">Cramer P, Langerbeins P, Eichhorst B, Hallek M. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). Eur J Haematol 2016; 96:9.</a></li></ol></div><div id="topicVersionRevision">Topic 83749 Version 99.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29540348" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17984187" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32206772" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34709929" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib plus Venetoclax (Ibr+Ven) versus Chlorambucil plus Obinutuzumab (Clb+O): the GLOW Study (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18411418" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23943357" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26492934" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37595283" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34310172" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32305093" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Acalabrutinib +/- obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: ELEVATE-TN 4-year follow-up (abstract S148)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36511784" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34974526" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34974526" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35810754" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33054121" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30501481" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30530801" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34274940" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26702066" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32704159" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Second cancer incidence in CLL patients receiving BTK inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31400009" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24699307" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25555420" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29483101" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32726539" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34086865" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34521099" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31365801" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35427411" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37142374" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30522969" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31628428" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26639149" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29880603" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35377947" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37163621" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37163621" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31166681" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32888452" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27178240" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29715056" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31990291" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34050972" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31141631" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Ibrutinib and Venetoclax for First-Line Treatment of CLL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31295041" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31433936" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Ibrutinib and Venetoclax for First-Line Treatment of CLL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32795224" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33027809" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34110383" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34534514" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34618601" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35196370" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35108374" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35654052" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37363867" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37944541" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38078508" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26332019" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
